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Abstract
Background: Neonatal hypothermia is an important challenge associated with morbidity and mortality. Preventing
neonatal hypothermia is important in high-resource countries, but is of fundamental importance in low-resource
settings where supportive care is limited.
Kangaroo mother care (KMC) is a low-cost intervention that, whenever possible, is strongly recommended for
temperature maintenance. During KMC, the World Health Organization (WHO) guidelines recommend the use of a
cap/hat, but its effect on temperature control during KMC remains to be established.
In the hospitals participating in the projects of the non-governmental organization CUAMM, KMC represents a
standard of care, but the heads of the babies often remain uncovered due to local habits or to the unavailability
of a cap. The aim of the present study will be to assess the effectiveness and safety of using a woolen cap in
maintaining normothermia in low-birth-weight infants (LBWI) during KMC.
Methods/design: This is a multicenter (three hospitals), multicountry (three countries), prospective, unblinded,
randomized controlled trial of KMC treatment with and without a woolen cap in LBWI. After obtaining parental
consent, all infants with a birth weight below 2500 g and who are candidates for KMC, based on the clinical
decision of the attending physician, will be assigned to the KMC with a woolen cap group or to the KMC without
a woolen cap group in a 1:1 ratio according to a computer-generated, randomized sequence. The duration of the
study will be until the patient’s discharge, with a maximum treatment duration of 7 days.
The primary outcome measure will be whether the infants’ temperatures remain within the normal range (36.5–37.
5 °C) in the course of KMC during the intervention. In all participants, axillary temperature will be measured with a
digital thermometer four times per day. In addition, maternal and room temperature will be recorded.
Secondary outcome measures will be: episodes of apnea; sepsis; mortality before hospital discharge; in-hospital
growth; and age at discharge.
Discussion: The findings of this study will be important for other units/settings in high- as well low-resource
countries where KMC is routinely performed. Based on the results of the present study, we could speculate whether
the use of a woolen cap may help to maintain the neonate within the normal thermal range. Furthermore,
potential complications such as hyperthermia will be strictly monitored and collected.
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Background
The days and weeks following childbirth – the postnatal
period – is a critical phase in the lives of mothers and
newborn babies. Most maternal and infant deaths occur
during this time [1]. In this period, neonatal
hypothermia is an important challenge associated with
morbidity and mortality [2]. Hypothermia increases the
newborn’s metabolic requirements and is associated with
hypoglycemia, hypoxia, and ultimately severe infections
and newborn mortality [3]. Preventing neonatal
hypothermia is important in high-resource countries,
but is of fundamental importance in low-resource set-
tings where supportive care is limited.
Kangaroo mother care (KMC) is a low-cost interven-
tion that has the potential to prevent many complica-
tions associated with preterm birth and may also
provide benefits to full-term newborns [4].
KMC is care of a small baby who is continuously car-
ried in skin-to-skin contact by the mother and exclu-
sively breastfed (ideally). It is considered the best way to
keep a small baby warm and it also helps to establish
breastfeeding. KMC can be started in the hospital as
soon as the baby’s condition permits (i.e., the baby does
not require special treatment, such as oxygen or intra-
venously administered fluids) [5].
Whenever possible, KMC is strongly recommended
for temperature maintenance [4]. During KMC, the
World Health Organization (WHO) guidelines recom-
mend the following approach: “clothe the baby with a
pre-warmed shirt open at the front, a napkin, a hat, and
socks” [5].
Previous studies show that neonatal heat loss following
delivery may be reduced or prevented by the application
of simple woolen hats [6–8], but the effect of a cap on
thermal control of neonates during the first postnatal
days remains to be defined. On the other hand, hyper-
thermia should also be avoided [9, 10].
Doctors with Africa CUAMM is a non-governmental
organization supporting health programs in different
African countries. In the hospitals participating in the
CUAMM projects, KMC represents a standard of care,
but the heads of the babies often remain uncovered due
to local habits or, more simply, to the unavailability of a
cap. However, although WHO guidelines recommend
the use of a cap/hat during KMC, the effect on neonatal
temperature during the days and weeks following child-
birth has not been previously studied. It is unknown
whether covering the head of the neonate with a woolen
cap during KMC may help temperature maintenance.
The results of the present study will allow us to under-
stand whether the use of a cap during KMC is effective
and safe.
Previous studies suggest that neonatal heat loss follow-
ing delivery may be reduced or prevented by the applica-
tion of a woolen hat [6–8]. These studies assessed
patients immediately after birth and for a short period.
On the other hand, hyperthermia can be dangerous to
the newborn infant and should also be avoided [9, 10].
To our knowledge, there are no previously published
studies that have evaluated the effect of using a woolen
cap in the course of KMC.
The aim of the present study will be to assess the ef-
fectiveness and safety of using a woolen cap in maintain-




This is a multicenter, prospective, unblinded, random-
ized clinical trial of KMC treatment with and without a
woolen cap in LBWI.
Setting
The study will be conducted at three hospitals that have
three different levels of healthcare in three African coun-
tries where Doctors with Africa CUAMM has ongoing
projects on maternal-neonatal health. They are:
1. Central Hospital of Beira in Mozambique (5555
deliveries – CUAMM data 2013), which is a
governmental hospital (III level) (Mozambique:
neonatal deaths, 34 % of all under-5 deaths; neonatal
mortality rate: 30 per 1000 live births; source:
Countdown to 2015, The 2014 Report) (http://
www.mediciconlafrica.org content/uploads/sites/2/
2015/09/Health_and_Devel_71_giu15-BASSA.pdf )
2. St. Luke Wolisso Hospital in Ethiopia (3323
deliveries – CUAMM data 2013), which is a no-
profit zonal hospital (II level) (Ethiopia: neonatal
deaths, 43 % of all under-5 deaths; neonatal mortal-
ity rate: 29 per 1000 live births; source: Countdown
to 2015, The 2014 Report) (http://www.mediciconla-
frica.org content/uploads/sites/2/2015/09/
Health_and_Devel_71_giu15-BASSA.pdf )
3. Aber Hospital in Uganda (1872 deliveries –
CUAMM data 2013), which is a no-profit rural
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hospital (I level) (Uganda: neonatal deaths, 33 % of
all under-5 deaths; neonatal mortality rate 23 per






Infants satisfying the following inclusion criteria will be
eligible to participate in the study:
1. Birth weight below 2500 g (and)
2. Candidate to KMC treatment (and)
3. Parental consent: a written informed consent will be
obtained by a member of the neonatal team involved
in the study from a parent or guardian before KMC
treatment
Exclusion criteria
1. Major congenital malformations
2. Twins
3. Parental refusal to participate in the study
Procedure
After obtaining parental consent, all infants with a birth
weight below 2500 g and who are candidates for KMC,
based on the clinical decision of the attending physician,
will be assigned to the KMC with a woolen cap group
(KMC + cap) or to the KMC without a woolen cap group
(KMC group). All the caps used for the study are hand-
made by a group of volunteers in Padova. The material
(wool) was provided by CUAMM and sizes were
standardized.
The procedure of initiating, maintaining and stopping
the KMC will be based on WHO guidelines [5]. Mothers
will be trained in monitoring the baby’s condition and in
recognizing dangerous clinical signs during KMC [5]. The
duration of the study will be until the patient’s discharge,
with a maximum treatment duration of 7 days. In case of
documented neonatal hypothermia (temperature below
36.5 °C) or hyperthermia (temperature above 37.5 °C) dur-
ing the course of the study, the pre-warmed blanket will
be added or removed. In case of maternal hyperthermia,
we will ask the woman to wear lighter clothes. In these
cases, neonatal and maternal temperatures will be mea-
sured every hour until the normal range is reached.
Primary outcome measure
The primary outcome measure will be whether the in-
fants’ temperatures remain within the normal range
(36.5–37.5 °C) in the course of KMC during the inter-
vention. In all participants, axillary temperature will be
measured with a digital thermometer (C202; Terumo,
Tokyo, Japan) every 6 hours during KMC treatment.
Maternal and room temperature will be registered at the
same time. Room temperature will be measured at the
same times (every 6 hours) by using the same wall
thermometers (Oregon Scientific RMR262) in all three
study sites.
Secondary outcome measures
1. Episodes of apnea, defined as the need for sustained
stimulation to initiate breathing
2. Sepsis, defined as the presence of at least two of the
following clinical signs: lethargy, persistent apnea,
poor feeding; fever
3. Mortality before hospital discharge
4. In-hospital growth, defined as weight at discharge
Generalizability
The findings of this study will be important for other
units/settings in high- as well low-resource countries
where KMC is routinely performed. Based on the results
of the present study, we could speculate whether the use
of a woolen cap may help to maintain the neonate
within the normal thermal range. Furthermore, potential
complications such as hyperthermia will be strictly mon-
itored and collected.
Sample size
The lack of information about this topic (temperature
during KMC in the specific scenario of head covering)
prevented us from obtaining a mathematical estimation
of the sample size. Thus, the sample size was arbitrarily
defined in order to take into account the enrollment rate
of each hospital. According to the number of admissions
in each participating hospital, we decided to enroll a
total of 300 subjects (150 in the cap group and 150 in
the uncovered head group) as follows: 150 at Central
Beira Hospital, 90 at St. Luke Wolisso Hospital and 60
at Aber Hospital.
Recruitment
Written and oral information will be offered to parents
by the attending nurse or physician prior to starting
KMC treatment. Informed written consent will be signed
by a parent. A senior investigator will be available at all
times to discuss concerns raised by parents or clinicians
during the course of the trial.
Randomization
Eligible infants will be assigned to the KMC + cap or
the KMC group in a 1:1 ratio according to a
computer-generated, randomized sequence for each
participating hospital. The randomized allocation will
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be concealed in double-enclosed, opaque, sealed, and
sequentially numbered envelopes prepared at the
University Hospital of Padua.
In the KMC room, the next sequential randomization
envelope will be opened only when the attending oper-
ator considers the infant to be eligible. The assigned
procedure (KMC + cap or KMC group) will be then per-
formed. Cross-over will not be allowed. Analysis will be
done as per intention-to-treat. A flow diagram of patient
randomization is reported in Fig. 1.
Blinding
Due to the characteristics of the intervention, neither
caregivers nor outcome assessors will be masked to
treatment allocation. However, the statistician who will
perform data analysis will be blind to treatment alloca-
tion. To minimize bias, strict criteria and definitions will
be maintained during the trial.
Guidelines for management
Before starting the study, all those involved in the study
will participate in a meeting where all the details of the
study will be presented. Midwives and nurses who are
responsible of the maternal and neonatal management
during KMC treatment will be educated on the
temperature measurements in terms of correct modality
(axillary), time of the study, and data collection. Neo-
natal, maternal and room temperature will be collected
four times/day (6.00 am, 12.00 am, 6.00 pm, and
12.00 pm).
Data collection
Data will be recorded in a data sheet designed for this
study. All data will be collected by an observer who is
not involved in the care of the neonates. The following
clinical information will be registered: eligibility, ante-
natal history, randomization, all data above listed in the
‘Primary outcome measure’ and ‘Secondary outcome
measures’ sections. Further information will be collected
on expected serious adverse events (SAEs). Personal in-
formation about potential and enrolled participants will
be collected, shared, and maintained in order to protect
confidentiality before, during, and after the trial by the
local principal investigator (PI) in a personal password-
protected PC. The PI and the members of the Steering
Committee located in Padua will have access to the final
trial dataset.
Statistical analysis
Analysis will be performed as per intention-to-treat.
Continuous data will be expressed as mean and standard
deviation (SD) or median and interquartile range (IQR).
The effect of the treatment on primary outcome will be
assessed using a Poisson model adjusting for hospital
and a set of clinically relevant confounders (maternal
temperature, environmental temperature, birth weight,
postnatal age). The logarithm of the number of measure-
ments during hospital stay will be used as an offset, in
order to take into account the different lengths of hos-
pital stay of each participant. The effect of the treatment
on the number of episodes of apnea will be assessed
Fig. 1 Flow diagram of patient randomization
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using a Poisson model adjusting for hospital and a set of
clinically relevant confounders (neonatal and maternal
temperatures, environmental temperature, birth weight,
postnatal age). The logarithm of the number of measure-
ments during hospital stay will be used as an offset. The
effect of the treatment on binary secondary outcome
(sepsis and mortality before hospital discharge) will be
assessed using a logistic regression model adjusting for
hospital and birth weight. The effect of the treatment on
continuous secondary outcome (in-hospital growth) will
be assessed using a regression model adjusting for hos-
pital. Statistical analysis will be performed using R 3.2.2
software (R Foundation for Statistical Computing,
Vienna, Austria) [11]. A p value less than 0.05 will be
considered statistically significant.
Duration of study
In this study, 300 infants will be recruited. The trial will
terminate when the last recruited infant is discharged
from hospital, or dies.
Based on a recent study conducted by our group at
the Central Hospital of Beira, Mozambique, we consider
that we will perform the study in about 14 months
(Table 1).
The study will be conducted – simultaneously – at the
three participating hospitals.
Ethical considerations
Written parental consent is necessary before enrollment
of the patients in the study. We consider that there will be
no risks for either study group (patients treated with or
without a woolen cap). Hypothermic as well as hyperther-
mic episodes will be strictly monitored in both groups.
Ethics Committee approval
The study was approved by the Ethics Committees for
Human Investigation of the three participating hospitals.
At the Central Hospital of Beira the study was approved
by the Comitè Nacional di Bioetica para a Saude, Minis-
terio da Saude (REF: 348/CNBS/15: IRB00002657;
Maputo, Mozambique; 8 December 2015); at St. Luke
Wolisso Hospital the study was approved by the Lacor
Hospital Institutional Research and Ethics Committee
(REF: LHIREC N.: 016/03/15; Gulu, Uganda; 30 May
2015); at Aber Hospital the study was approved by the
Oromia Regional Health Research Ethical Review
Committee Bureau (REF: BEFOABTFH 3657/1-8; Addis
Ababa, Ethiopia; 24 June 2015).
Compliance to protocol
Compliance will be defined as full adherence to
protocol. Compliance with the protocol will be en-
sured by some members of the project (DM, TS, SM,
WM) who are responsible for local data collection.
They will monitor adherence to the study protocol
weekly and will input the patients’ data in an Excel
data sheet. Double data entry will be performed by
two independent members at each center to promote
data quality.
Missing data
Investigators and study staff will be trained on the import-
ance of completion of the study period of enrolled patients.
Parents will also be informed about this crucial aspect to
reduce dropout, and a local investigator will be available at
each site any time that the parents may need further infor-
mation or clarification during the study period.
Data Safety and Monitoring Board
Safety measures will include incidence, severity and causal-
ity of reported SAEs, represented by changes in occurrence
of the expected common neonatal complications and the
development of unexpected SAEs. SAE will be defined as
unexpected death, apnea not responding to vigorous stimu-
lation, severe hyperthermia (temperature >39 °C) and
hypothermia (temperature <35 °C). All SAEs will be
followed until complete resolution or until the clinician re-
sponsible for the care of the recruited patient considers the
event to be chronic or the infant to be stable.
A monitoring board, including an independent asses-
sor (not involved in the study) from the University of
Padova and assessors from each participating hospital,
will review all the deaths and adverse events. If there is a
reasonable suspected causal relationship with the inter-
vention, SAEs will be reported to the Ethics Committee
to guarantee the safety of the participants.
An interim analysis will be performed on the primary
endpoint and on SAEs from the first 100 enrolled in-
fants. The interim analysis will be performed by the stat-
istician, who is blinded for the treatment allocation and
who will report to the PI. The PI will discuss the results
of the interim analysis with the monitoring board and
the trial will be ended in case of harm. Criteria for
Table 1 Duration of the study
Time 2 months 3 months 6 months 1 month 2 months
Task Preparation of the protocol and Case Report
Form (CRF), and material (i.e.. thermometer,
woolen cap); (completed)
Ethics and Ministerial Committee
approval; (completed)




Done x x x (started in January 2016)
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stopping for harm include: a statistically significant dif-
ference in the primary outcome between the treatment
groups; and a reasonable suspected causal relationship
between the intervention and SAEs.
Confidentiality
Only the local PI will have access to the Excel database
with an assigned personal account and password. Subjects
will be identified by sex, birth date, and assigned trial
number, during and after the trial, in accordance with per-
sonal data protection law.
Access to data
The PIs of each site will have complete access to the
final trial dataset, and no contractual agreement exists to
limit such access for the investigators.
Dissemination policy
The results of the trial are expected to be published in a
scientific journal and presented at medical seminars and
conferences. The final reporting will follow the Consoli-
dated Standards of Reporting Trials (CONSORT) State-
ment guidelines (http://www.consort-statement.org).
Discussion
There are unique features of this trial compared to prior
studies on KMC. World Health Organization guidelines
recommend the use of a cap during KMC treatment [5],
but evidence for this practice is lacking. In this trial, we
will assess the efficacy and safety of using a woolen cap
during KMC treatment.
Trial status
The trial was approved by the Ethics Committees of the
participating hospitals. Enrollment of patients started in
January 2016.
Abbreviations
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